openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.
Warnings sections page 1 of 1 · 1 matching rows.
warnings and cautions
5 WARNINGS AND PRECAUTIONS Thromboembolic disorders: Discontinue if thrombosis or thromboembolism occurs ( 5.1 ) Allergic reactions: Consider discontinuing if allergic reactions occur ( 5.2 ) Decreased glucose tolerance: Monitor prediabetic and diabetic women receiving hydroxyprogesterone caproate ( 5.3 ) Fluid retention: Monitor women with conditions that may be affected by fluid retention, such as preeclampsia, epilepsy, cardiac or renal dysfunction ( 5.4 ) Depression: Monitor women with a history of clinical depression; discontinue hydroxyprogesterone caproate if depression recurs ( 5.5 ) 5.1 Thromboembolic Disorders Discontinue hydroxyprogesterone caproate if an arterial or deep venous thrombotic or thromboembolic event occurs. 5.2 Allergic Reactions Allergic reactions, including urticaria, pruritus and angioedema, have been reported with use of hydroxyprogesterone caproate or with other products containing castor oil. Consider discontinuing the drug if such reactions occur. 5.3 Decrease in Glucose Tolerance A decrease in glucose tolerance has been observed in some patients on progestin treatment. The mechanism of this decrease is not known. Carefully monitor prediabetic and diabetic women while they are receiving hydroxyprogesterone caproate. 5.4 Fluid Retention Because progestational drugs may cause some degree of fluid retention, carefully monitor women with conditions that might be influenced by this effect (e.g., preeclampsia, epilepsy, migraine, asthma, cardiac or renal dysfunction). 5.5 Depression Monitor women who have a history of clinical depression and discontinue hydroxyprogesterone caproate if clinical depression recurs. 5.6 Jaundice Carefully monitor women who develop jaundice while receiving hydroxyprogesterone caproate and consider whether the benefit of use warrants continuation. 5.7 Hypertension Carefully monitor women who develop hypertension while receiving hydroxyprogesterone caproate and consider whether the benefit of use warrants continuation.
6 ADVERSE REACTIONS For the most serious adverse reactions to the use of progestins, see Warnings and Precautions (5) . In a study where the hydroxyprogesterone caproate intramuscular injection was compared with placebo, the most common adverse reactions reported with hydroxyprogesterone caproate intramuscular injection (reported incidence in ≥ 2% of subjects and higher than in the control group) were: injection site reactions (pain [35%], swelling [17%], pruritus [6%], nodule [5%]), urticaria (12%), pruritus (8%), nausea (6%), and diarrhea (2%). ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact AuroMedics Pharma LLC at 1-866-850-2876 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch . 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to the rates in the clinical trials of another drug and may not reflect the rates observed in practice. In a vehicle (placebo)-controlled clinical trial of 463 pregnant women at risk for spontaneous preterm delivery based on obstetrical history, 310 received 250 mg of hydroxyprogesterone caproate and 153 received a vehicle formulation containing no drug by a weekly intramuscular injection beginning at 16 to 20 weeks of gestation and continuing until 37 weeks of gestation or delivery, whichever occurred first. [ See Clinical Studies (14.1) . ] Certain pregnancy-related fetal and maternal complications or events were numerically increased in the hydroxyprogesterone caproate-treated subjects as compared to control subjects, including miscarriage and stillbirth, admission for preterm labor, preeclampsia or gestational hypertension, gestational diabetes, and oligohydramnios (Tables 1 and 2). Table 1 Selected Fetal Complications 1 N = Total number of subjects enrolled prior to 20 weeks 0 days 2 N = Total number of subjects at risk ≥ 20 weeks Pregnancy Complication Hydroxyprogesterone Caproate n/N Control n/N Miscarriage (< 20 weeks) 1 5/209 0/107 Stillbirth (≥ 20 weeks) 2 6/305 2/153 Table 2 Selected Maternal Complications 1 Other than delivery admission. Pregnancy Complication Hydroxyprogesterone Caproate N=310 % Control N=153 % Admission for preterm labor 1 16.0 13.8 Preeclampsia or gestational hypertension 8.8 4.6 Gestational diabetes 5.6 4.6 Oligohydramnios 3.6 1.3 Common Adverse Reactions: The most common adverse reaction with intramuscular injection was injection site pain, which was reported after at least one injection by 34.8% of the hydroxyprogesterone caproate group and 32.7% of the control group. Table 3 lists adverse reactions that occurred in ≥ 2% of subjects and at a higher rate in the hydroxyprogesterone caproate group than in the control group. Table 3 Adverse Reactions Occurring in ≥ 2% of Hydroxyprogesterone Caproate-Treated Subjects and at a Higher Rate than Control Subjects Preferred Term Hydroxyprogesterone Caproate N=310 % Control N=153 % Injection site pain 34.8 32.7 Injection site swelling 17.1 7.8 Urticaria 12.3 11.1 Pruritus 7.7 5.9 Injection site pruritus 5.8 3.3 Nausea 5.8 4.6 Injection site nodule 4.5 2.0 Diarrhea 2.3 0.7 In the clinical trial using intramuscular injection, 2.2% of subjects receiving hydroxyprogesterone caproate were reported as discontinuing therapy due to adverse reactions compared to 2.6% of control subjects. The most common adverse reactions that led to discontinuation in both groups were urticaria and injection site pain/swelling (1% each). Pulmonary embolus in one subject and injection site cellulitis in another subject were reported as serious adverse reactions in hydroxyprogesterone caproate-treated subjects. 6.2 Postmarketing Experience The following adverse reactions have been identified during postapproval use of hydroxyprogesterone caproate. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. Body as a whole : Local injection site reactions (including erythema, urticaria, rash, irritation, hypersensitivity, warmth); fatigue; fever; hot flashes/flushes Digestive disorders : Vomiting Infections : Urinary tract infection Nervous system disorders : Headache, dizziness Pregnancy, puerperium and perinatal conditions: Cervical incompetence, premature rupture of membranes Reproductive system and breast disorders: Cervical dilation, shortened cervix Respiratory disorders : Dyspnea, chest discomfort Skin : Rash
adverse reactions table
<table cellspacing="0" cellpadding="0" border="0" width="100%"><caption>Table 1 Selected Fetal Complications </caption><colgroup><col width="31.78%"/><col width="38.4%"/><col width="29.82%"/></colgroup><tfoot><tr><td colspan="3"><sup>1</sup> N = Total number of subjects enrolled prior to 20 weeks 0 days <sup>2</sup> N = Total number of subjects at risk ≥ 20 weeks </td></tr></tfoot><tbody><tr styleCode="Botrule"><td styleCode="Lrule Rrule" valign="middle"><content styleCode="bold">Pregnancy Complication</content> </td><td styleCode="Rrule" align="center" valign="middle"><content styleCode="bold">Hydroxyprogesterone Caproate</content> <content styleCode="bold">n/N</content> </td><td styleCode="Rrule" align="center" valign="middle"><content styleCode="bold">Control</content> <content styleCode="bold">n/N</content> </td></tr><tr styleCode="Botrule"><td styleCode="Lrule Rrule" valign="middle">Miscarriage (< 20 weeks)<sup>1</sup> </td><td styleCode="Rrule" align="center" valign="middle">5/209 </td><td styleCode="Rrule" align="center" valign="middle">0/107 </td></tr><tr><td styleCode="Lrule Rrule" valign="middle">Stillbirth (≥ 20 weeks)<sup>2</sup> </td><td styleCode="Rrule" align="center" valign="middle">6/305 </td><td styleCode="Rrule" align="center" valign="middle">2/153 </td></tr></tbody></table>